Pharmaceutical R&D Productivity: The Role of Alliance


Big Data


In recent years, the major research-intensive biopharmaceutical companies (big pharma) have come face to face with a perfect storm of eroding profit margins from blockbuster expiration and generic competition coupled with growing R&D expenses and declining advances in truly novel therapeutics. With long-term research divisions shed in favor of short-term outsourcing options and with public good will at historic lows, industry innovators have sought to reinvent the model of big pharma, its relationship in public-private partnerships, and the role of technology and technology policy in reform. In this paper, we highlight a number of the major alliances reshaping the industry and the role of government, research institutions, and other players in the public-private interface in these endeavors. In particular, this paper looks beyond traditional biotechnology parternships and focuses instead on the developing consortia between biopharmaceutical companies and with clinical research organizations and academic institutions. We examined each alternative model of alliance, identified specific hurdles and potentials for increased productivity.



PricewaterhouseCoopers. Pharma 2020: The vision; Which path will you take? PricewaterhouseCoopers. June 2007; 1-52. Available from: BioValley, Basel, Switzerland. Accessed March 23, 2013.

Congressional Budget Office. Research and Development in the Pharmaceutical Industry. Congress of the United States, Congressional Budget Office. October 2006.

Terblanche N. New pharmaceutical product development: Barriers to overcome and opportunities to exploit. Journal Of Commercial Biotechnology [serial online]. July 2008;14(3):201-212. Available from: Business Source Premier, Ipswich, MA. Accessed March 9, 2013.

Kola I, Landis J. Can the Pharmaceutical Industry Reduce Attrition Rates? Nature Reviews Drug Discovery. August 2004;3:711-715.

Danzon, Patricia M.; Nicholson, Sean; and Pereira, Nuno Sousa. “Productivity in Pharmaceutical-Biotechonology R&D: the Role of Experience and Alliancesâ€, Journal of Health Economics, Vol. 24, No. 2, March 2005, pp: 317-339.

Hoang, HA; and Rothaermel, Frank T. “The Effect of General and Partner-Specific Alliance Experience on Joint R&D Project Performanceâ€, Academy of Management Journal, Vol. 48, No. 2, 2005, pp: 332-345.

Grabowski, Henry; and Kyle, Margaret. “Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivityâ€, in Economics of Corporate Governance and Mergers, ed. Gugler, Klaus and Yurtoglu, B. Burcin, published by Edward Elgar, Nov. 2008.

Schiele H. Early supplier integration: the dual role of purchasing in new product development. R&D Management [serial online]. March 2010;40(2):138-153. Available from: Business Source Premier, Ipswich, MA. Accessed February 21, 2013.

Yang S. Pharmaceutical innovation: AstraZeneca's experience in China. Mckinsey Quarterly [serial online]. March 2012;(1):93-95. Available from: Business Source Premier, Ipswich, MA. Accessed March 9, 2013.

Areddy J. Scientist Convicted of Stealing Merck Drugs. Wall Street Journal. June 2012. Available from: WSJ online. Accessed April 9, 2013.

Madhur Singh, Should Clinical Trials Be Outsourced? TIME, August 7, 2008,,8599,1830334,00.html.

Nourmohammadi N. FierceCROs Top 5 Strategic CRO/Pharma Partnerships. Fierce CRO Web site. June 14, 2012. Accessed April 5, 2013.

Miller J. CROs and CMOS Have Cause to Celebrate. Pharmaceutical Technology Europe [serial online]. October 2012;24(10):20-26. Available from: Business Source Premier, Ipswich, MA. Accessed April 4, 2013.

Getz KA. Insights from Today’s CRO Renaissance. Applied Clinical Trials Web Site. June 1, 2006. Accessed April 5, 2013.

Getz KA. Successful Outsourcing: Tracking Global CRO Usage. Applied Clinical Trials Web Site. August 17, 2009. Accessed April 5, 2013.

Kaitin K. 21st Century Bioinnovation. Pharmaceutical Technology [serial online]. June 2011;35(6):32. Available from: Business Source Premier, Ipswich, MA. Accessed April 12, 2013.

Collier R, McBride R. The Insider Perspective; Academic & Pharma Partnerships: Tapping the Ivory Tower for the Next Blockbuster. FiercePharma eBook. February 2012. Available from: FiercePharma. Accessed April 8, 2013.

Collier R, McBride R. Pitfalls, Horror Stories, and Cautionary Tales. Academic & Pharma Partnerships: Tapping the Ivory Tower for the Next Blockbuster FiercePharma eBook. February 2012. Available from: FiercePharma. Accessed April 8, 2013.

Toor S, McBride R. 20 Major Pharma-Academic Alliances in 2012. FierceBiotech Web Site. Accessed March 9, 2013.

Richards D, Dalton B. Collaboration in research protocol design: A case study exploring knowledge creation for the pharmaceutical industry and prescribing physicians. Journal Of Medical Marketing [serial online]. July 2009;9(3):213-220. Available from: Business Source Premier, Ipswich, MA. Accessed March 9, 2013.

Blakeslee W. Licensing, partnering, strategic alliances and university relationships. Journal Of Commercial Biotechnology [serial online]. March 2012;18(2):68-71. Available from: Business Source Premier, Ipswich, MA. Accessed March 9, 2013.

Groves P, Kayyali B, Knott D, Van Kuiken S. The ‘big data†revolution in healthcare: Accelerating value and innovation. Center for US Health System Reform, Business Technology Office. McKinsey & Company. January 2013.

Hede K. Project Data Sphere to make cancer clinical trial data publicly available. Journal of the National Cancer Institute. July 21, 2013.

Bhattacharjee Y. Pharma Firms Push for Sharing Of Cancer Trial Data. Science. 338:29. October 2012. Accessed Aug 6, 2013

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.